Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 6/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894190 | 1.00 | MMP2 (0.38) | MMP2CYP19A1ANPEPNR1H2NR1H3 | |
| SCHEMBL29697301 | 0.90 | BTK (0.39) | MMP2ANPEPNR1H2KCNA3BTK | |
| SCHEMBL3898037 | 0.90 | BTK (0.39) | MMP2ANPEPNR1H2KCNA3BTK | |
| SCHEMBL7727315 | 0.84 | BTK (0.46) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL7727313 | 0.84 | BTK (0.46) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL7731684 | 0.84 | BTK (0.46) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL12480680 | 0.84 | MMP2 (0.40) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL9907303 | 0.84 | MMP2 (0.40) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL13938226 | 0.80 | MMP2 (0.47) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL13938227 | 0.80 | MMP2 (0.47) | MMP2ANPEPNR1H2NR1H3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| CN-114667167-B | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| CN-114667167-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-4010080-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028643-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| US-7417024-B2 | Template-fixed peptidomimetics as inhibitors of serine proteases | POLYPHOR LTD. (CH) | 2008-08-26 | — | — | US | disclosed |
| US-7253146-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD (CH) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | MMP2 1545/4885CYP19A1 19/4885ANPEP 1719/4885 |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | MMP2 1545/4885CYP19A1 19/4885ANPEP 1719/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | MMP2 2027/4885CYP19A1 75/4885ANPEP 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.